NCT02569723View on ClinicalTrials.gov

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 16, 2015

Primary Completion Date

April 20, 2018

Study Completion Date

April 4, 2020

Conditions
Colon Adenocarcinoma
Interventions
DRUG

Carbon C 14 Oxaliplatin

Intravenous infusion

DRUG

Oxaliplatin

Intravenous infusion

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Edward Kim

OTHER

NCT02569723 - Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy | Biotech Hunter | Biotech Hunter